| Literature DB >> 35719420 |
Jessica L Swanson1,2, Pey-Shyuan Chin2,3, Juan M Romero2,3,4, Snigdha Srivastava1,2,4, Joshua Ortiz-Guzman1,2, Patrick J Hunt1,2,4, Benjamin R Arenkiel1,2,3,4.
Abstract
Neural circuits and the cells that comprise them represent the functional units of the brain. Circuits relay and process sensory information, maintain homeostasis, drive behaviors, and facilitate cognitive functions such as learning and memory. Creating a functionally-precise map of the mammalian brain requires anatomically tracing neural circuits, monitoring their activity patterns, and manipulating their activity to infer function. Advancements in cell-type-specific genetic tools allow interrogation of neural circuits with increased precision. This review provides a broad overview of recombination-based and activity-driven genetic targeting approaches, contemporary viral tracing strategies, electrophysiological recording methods, newly developed calcium, and voltage indicators, and neurotransmitter/neuropeptide biosensors currently being used to investigate circuit architecture and function. Finally, it discusses methods for acute or chronic manipulation of neural activity, including genetically-targeted cellular ablation, optogenetics, chemogenetics, and over-expression of ion channels. With this ever-evolving genetic toolbox, scientists are continuing to probe neural circuits with increasing resolution, elucidating the structure and function of the incredibly complex mammalian brain.Entities:
Keywords: calcium/voltage indicator imaging; cell type-specific; chemogenetics; neural circuit tracing; neurotransmitter/biosensors; optogenetics; targeted ablation; viral genetic technology
Mesh:
Substances:
Year: 2022 PMID: 35719420 PMCID: PMC9204427 DOI: 10.3389/fncir.2022.886302
Source DB: PubMed Journal: Front Neural Circuits ISSN: 1662-5110 Impact factor: 3.342
FIGURE 1Visual abstract. This review discusses the paramount goals in neural circuitry research, which are to (1) map neural circuit connectivity using viral tracing approaches, (2) monitor circuit function using methods such as electrophysiology and genetically encoded indicator/voltage/sensor imaging, and (3) manipulate neural circuits to interrogate function via targeted ablation, expression of exogenous ion channels, chemogenetics, or optogenetics. All of these approaches require creative genetic tools to implement them in genetically-defined populations of neurons.
FIGURE 2Genetic approaches toward achieving cell-type specificity. (A) Schematic of labeling neurons with different reporters using Cre (red) and Flp (green) recombinases separately. Cre and Flp-positive cells are visualized in yellow. (B) Schematic of labeling neurons with both Cre and Flp recombinases using the Con-Fon reporter, which is designed to be expressed only when both Cre and Flp recombinases exist. (C) Schematic of TRAP. The reporter of interest will be expressed only when Tamoxifen (TM) and neural activity (as indicated by cfos expression) exist in a TRAP + neuron. (D) Schematic of FLiCRE. When light and neuronal activity (as measured by an increase in calcium concentration) exist simultaneously, neurons will express the FLiCRE reporter of interest.
Properties of commonly used conventional (white) and viral neural tracers (blue).
|
| ||||||
| Name | Genome type | Onset (transport) | Duration | Transsynaptic labeling | Toxicity | |
|
| HSV-129 | dsDNA | Hours | Mice die 3–5 days after injection | Yes (Monosynaptic: H129-ΔTK-tdT) | H129-ΔTK-tdT causes toxicity in 3–5 days |
| AAV1, AAV9 | ssDNA | 2–3 weeks | Months | Yes (AAV1 is transsynaptic in GABAergic/ | Minimal | |
| CTB | By 24 h | 1–2 months | No | Minimal | ||
| PHA-L | 1–3 weeks | Several weeks | No | Minimal | ||
| DAs (10 kda) | 6–14 days | Several weeks | No | Minimal | ||
| WGA/WGA-HRP | 3–4 days | – | Yes | Minimal | ||
|
| HSV | dsDNA | Hours | Usually 5–7 days | Yes | Dependent on strain and replication competence |
| Pseudorabies virus | dsDNA | 2–3 weeks | Months | Yes | Dependent on strain and replication competence | |
| CAV-2 | dsDNA | 3–7 days | Months | No | Limited | |
| Rabies virus | ssRNA | About 2 days | Months | Yes (Monosynaptic: RABV) | Dependent on strain and replication competence | |
| AAV2-retro | ssDNA | 1–2 weeks | Months | No | Minimal | |
| CTB | By 24 h | 1–2 months | No | Minimal | ||
| FluoroGold | 7–10 days | Months | No | Minimal | ||
| DAs (3 kDa) | 10–15 days | Several weeks | No | Minimal | ||
| WGA/WGA-HRP | 3–4 days (WGA-HRP is more sensitive) | – | Yes | Minimal | ||
| HRP | 5–7 days (Slightly longer than WGA-HRP) | – | No | Minimal | ||
FIGURE 3Retrograde viral tracing strategies. (A) Non-transsynaptic retrograde tracing using retro-AAV or CAV-2. (B) Transsynaptic retrograde tracing using pseudotyped rabies virus is used to trace monosynaptic connections. Rabies G (RB) is provided in trans and neurons are pseudotyped with TVA receptor to endow cell-type specificity. Once a neuron expressing TVA and RG is infected with RABV expressing EnvA, the RABV may jump across one synapse in a retrograde manner.
FIGURE 4Anterograde viral tracing strategies. (A) Non-transsynaptic anterograde tracing using expression of a cytosolic or membrane-bound fluorescent reporter. (B) Non-transsynaptic anterograde tracing using expression of Synaptophysin fused to a fluorescent reporter. (C) Transsynaptic, monosynaptic tracing using the H129-ΔTK-tdT system. When TK is provided in trans, the H129 reporter virus may jump across one synapse in an anterograde manner.
FIGURE 5Mapping brain-wide connections with multiplexed, barcoded viral tools. (A) Multiplexed Analysis of Projections by Sequencing (MAPseq) uses barcoded viruses to identify projections from a single injection site. Barcodes are extracted from the injection site and from axons at the projections. (B) Brain-wide individual animal connectome (BRICseq) uses the same barcoded viral library strategy as MAPseq but for multiple sites in the brain. Different “zipcodes” are designated to a spatial location within the brain and small dissections of tissue are removed for analysis. Soma and projections are then determined by the total makeup of barcodes in the projections compared to soma. (C) Barcoded anatomy resolved by sequencing (BARseq) is a technique that combines MAPseq and in situ sequencing to maintain the physical position of neurons and their axons within the brain. (D) Rabies barcode interaction detection followed by sequencing (RABIDseq) uses rabies virus and sequencing to gather transcriptome data on mono-transsynaptic partners. Created with Biorender.com.
Commonly used GCaMP reporters.
| Class | Indicator | Emission wavelength (nm) | Description | References |
| GFP | GCaMP1.3/1.6 | 510 | Slow kinetics for calcium binding; unable to resolve single APs. | |
| GCaMP2 | 511 | Slow kinetics for calcium binding; unable to resolve single APs. | ||
| GCaMP3 | 513 | Adequate fluorescence at basal cell [Ca2+]. Unable to resolve single action potentials (APs) | ||
| GCaMP5A/D/G/K/L | 510 | Improved dynamic range (increased threefold from GCaMP3). Variants can be chosen according to their properties to fit particular experimental requirements. | ||
| GCaMP6f/m/s | 510 | Able to detect single APs. 6f has shortest half-decay time. Variants can be chosen according to their properties to fit experimental requirements. Adequate for imaging experiments over multiple weeks. | ||
| jGCaMP7 | 515 | Enhanced signal-to-noise ratio allows detection of individual spikes over wide fields of view (jGCaMP7s,f). Used for imaging of small processes thanks to the enhanced brightness (jGCaMP7b). | ||
| jGCaMP8 | ∼510 | Enhanced signal intensity, similar kinetics to GCaMP6. Well suited for bulk population recordings. | ||
| RFP | RCaMP1a | 630 | Brighter than RGECO, but lower calcium binding affinity and dynamic range. Not activated by blue light, making it suitable for use with optogenetics. | |
| RCaMP1.07 | 584 | Higher fluorescence than RGECO. Well suited for use with optogenetics. |
| |
| RCaMP2 | 583 | Strong single AP responses, very fast kinetics, suited for dual color calcium imaging with green fluorescent indicators. |
| |
| Multiple color variants | XCaMP | blue, green, yellow, red | Improved signal linearity. Adequate fluorescence at basal cell [Ca2+] (XCaMP-G). Enables measurement of fast-spike trains in individual neurons. |
Non-GCaMP-based genetically encoded calcium indicators, including GECOs and camgaroos.
| Class | Indicator | Emission wavelength (nm) | Description | References |
| GECO | G-GECO1-1.2 | ∼512 | Better than GCaMP3 for monitoring spontaneous Ca2 + oscillations. Higher fluorescence than GCaMP3. pH-sensitive. |
|
| B-GECO1 | 446 | Suited for multichromatic imaging. pH-insensitive compared to G-GECOs. Interference with mitochondrial autofluorescence. |
| |
| R-GECO1 | ∼600 | Greater dynamic range and higher calcium binding affinity than RCaMP. Susceptible to artifact-induced excitation with blue and green light. | ||
| NIR-GECO2/2G | 685/40 | Near-infrared calcium indicators susceptible to infrared light-induced activation. Lower brightness and slower kinetics than standard green and red GECIs. |
| |
| GEX-GECO1 | ∼510 | Fast kinetics, large dynamic range. |
| |
| GEM-GECO1 | 511/455 | Good signal range, mitochondrial autofluorescence does not interfere with its activity. |
| |
| jRGECO1a | 630 | Faster than RCaMP. |
| |
| Camgaroos | Camgaroo-1 | 513 | Unable to detect single APs. Exhibits slower kinetics than latest GCaMP versions. | |
| Camgaroo-2 | 535 | Unable to detect single APs. Exhibits slower kinetics than latest GCaMP versions. |
Commonly used GEVIs.
| Class | Indicator | Fluorescence reporter (Emission wavelength nm) | Description | References |
| Ion Channel-FPs | Shaker Kv-based FlaSH | FLaSH-GFP (505) | Slow, cannot resolve APs. Potential co-assembly with native channel subunits. Low fluorescence change. | |
| SPARC | GFP (505) | Faster than FLaSH-based sensors, reports pulses as low as 2ms. Does not inactivate during extended depolarizations. Low fluorescence change. | ||
| FlaSH with split FP | Depends on FP | Low fluorescence change; slow kinetics. |
| |
| FRET | VSFP1/2s, CR | CFP (477) | Reliable membrane targeting. Limited by slower response kinetics compared to VSFP butterflies. | |
| Chimeric VSFP butterflies | Citrine (542) | Faster than previous VSFPs. Reports membrane voltage oscillations up to 200 Hz. |
| |
| Nabi | Nabi1: mKO (559), UKG (499); Nabi2: Clover (515), mRuby2 (600) | Better SNR, faster than VSFP butterflies and VSFP-CR. |
| |
| Mono-chromatic FPs | VSFP3s | Citrine (529) mOrange (562) TagRFP (584) mKate2 (633) | VSFP3 faster than VSFP2.3. Red-shifted VSFP3 available. | |
| Arclight | GFP (507) | Robustly reports AP and subthreshold events and reveals electrical signals in neurite branches. | ||
| Bongwoori | s.e.pHluorin A227D (509) | Faster kinetics than Arclight. Resolves 60 Hz APs. |
| |
| CpFP-based VSFPs | Depends on the FP | Weaker fluorescence than red shifted indicators. However, the red shifted indicators are still slower and weaker compared to other VSFPs. |
| |
| FlicR | cpmApple (560) | Bright and fast-read voltage indicator. Brighter than ArcLight Q239, similar kinetics to ArcLight Q239. |
| |
| ASAP family | CpGFP (509) | ASAP1 has on-off kinetics of ∼2ms, detects APs and subthreshold changes. Tracks AP trains up to 200 Hz. ASAP2 more sensitive, suited for 2p imaging. | ||
| Rhodopsin fluorescent probes | Arch | Arch (687nm), Arch (D95N; 687nm) | Fast and sensitive voltage sensor but it is very dim. |
|
| QuasArs | QuasAr1 (H95Q) 715 nm | Both QuasAr1 and QuasAr2 have enhanced fluorescence compared to Arch (D95N). |
| |
| Archons | Archon 1 retinal cofactor (637 nm) | Archon1 follows small, high-speed voltage changes in cultured neurons; brighter than QuasArs |
| |
| Opsin/FRET | Ace-mNeon | mNeonGreen (517 nm) | Responds five to six times as fast as MacQ-mCitrine and ASAP1 indicator; more photostable. |
|
| VARNAM | MRuby3 N81S (565 nm) | Resolves APs with sensitivity and kinetics comparable to Ace-mNeon. |
| |
| MacQ-m Citirine | mCitirine (529nm) | Faster kinetics than Arclight. Not brighter than Arclight but with a comparable or better SNR. |
| |
| QuasAr2-mOrange2 | Retinal cofactor (715 nm) | Outperforms red-shifted ASAP1 and eFRET GEVIs in sensitivity, speed, SNR and photostability, but requires intense laser illumination. |
| |
| Fret-Dye | Voltron | JF525 (532 nm) | Brighter than Ace2N-mNeon and ASAP2f in cell culture. Improved photostability compared to Ace2N-mNeon. In mice, allows single-trial recording of spikes and subthreshold voltage signals from dozens of neurons simultaneously for 15 min. |
|
| Other | hVOS | EGFP-F + DPA (505 nm) | Improved sensitivity and temporal resolution compared to previous GFP based probes. |
|
| VoltageSpy | (546 nm) | Robust, single-trial optical detection of APs at soma. Reports APs in axons and dendrites. |
|
AP, action potential; SNR, signal-to-noise ratio.
Properties and applications of genetically encoded neurotransmitter sensors.
| Sensor | Excitation/Emission wavelengths (nm) | Detection range | ON kinetics (ms) | Applications | References |
|
| |||||
| iGluSnFR | 490/510 | 1 μM–10 mM | 15 | ||
| SF-iGluSnFR-A184S | 490/510 | 1 μM–10 mM | 85 | Mouse, ferret |
|
| iGluu | 490/510 | 10 μM–10 mM | 0.7 | N/A | ( |
| SF-Venus-iGluSnFR | 515/528 | 1 μM–10 mM | N/A | Mouse |
|
| R-iGluSnFR1 | 562/588 | 1 μM–10 mM | N/A | N/A |
|
|
| |||||
| iGABASnFR | 485/510 | 1 μM–10 mM | ∼25 | Zebrafish, mouse |
|
|
| |||||
| iAchSnFR | 485/510 | 0.1–100 μM | ∼25 | Zebrafish, mouse, |
|
| iNicSnFR | 485/535 | 1 μM–10 mM | ∼1000 | Zebrafish |
|
| GACh3.0 | 492/510 | 0.1–100 μM | 312 | Mouse, |
|
|
| |||||
| iSeroSnFR | 490/512 | 330 pM–5 mM | 0.5 | Mouse |
|
| sLight1.3 | 490/516 | 1 nM–10 μM | N/A | Mouse |
|
| GRAB5–HT | 490/510 | 1 nM–1 μM | 200 | Mouse |
|
|
| |||||
| dLight1.1 | 490/516 | 10 nM–10 μM | 10 | Mouse |
|
| dLight1.2 | 490/516 | 10 nM–10 uM | 9.5 | Mouse |
|
| dLight1.3b | 490/516 | 100 nM–100 μM | N/A | Mouse, rat |
|
| dLight1.4 | 490/516 | 1 nM–1 μM | N/A | Mouse, rat |
|
| GRABDA1m | 490/510 | 10 nM–1 μM | 80 | Mouse, |
|
| GRABDA1h | 490/510 | 1 nM–10 μM | 110 | Mouse, |
|
| R-dLight1 | 562/588 | 0.01–100 μM | 14 | Mouse, rat |
|
|
| |||||
| nLight1.3 | 490/516 | 0.1–100 μM | N/A | Mouse |
|
| GRABNE1m | 490/510 | 0.1–100 μM | 72 | Mouse, zebrafish |
|
|
| |||||
| OxLight1 | 470/560 | 0.1–10 μM | 500–700 | Mouse |
|
|
| |||||
| MTRIAOT | 490/510 | 0.01–1 μM | 12,000 | Mouse |
|
| GRABOT1.0 | 490/510 | 0.001–1 μM | 500 | Mouse |
|
Adapted from
Commonly used pharmacological agents in neural circuit studies.
| Compound | Description | References |
| Tetrodotoxin (TTX) | Puffer fish-derived chemical that selectively blocks voltage gated sodium channels most associated with the action potential. Most useful in electrophysiologic confirmation of a monosynaptic connection between neurons. |
|
| APV | Blocks the NMDA glutamate receptor. It has been critical in understanding both long term depression and potentiation. |
|
| CNQX | A stable and selective blocker of AMPA receptors, drawn from a broad class of engineered compounds known as quinoxalinediones. |
|
| Tetanus toxin | A bacterially derived protein that can inhibit SNARE mediated exocytosis, thereby inhibiting neurotransmission. In 1995, this technology was made to be expressed directly by neurons, paving the way for current cell-type specific vesicular release silencing. |
Opsins are commonly used in optogenetics with their salient properties.
| Effect | Variant | Description of opsin | Peak activation wavelength (nm) | References |
| Excitatory (de-polarizing) | ChR2 | Most widely used cation conducing opsin, non-specific cation channel from | 470 |
|
| ChR/T159C and ChR2/H134 | Mutations in ChR2 that induce relatively larger photocurrents. | 450, 470 | ||
| ReaChR | Red-shifted variant of ChR2. | 590 |
| |
| ChETA (E123T) | ChR2 mutations that induce more rapid kinetics, at the cost of smaller photocurrents. | 490 |
| |
| SFO/SSFO | Step-opsins with delayed closing of ion channel for sustained action (current will continue upon cessation of light); quickly closes with red-light pulse. | 470 (closed with 590) |
| |
| ChrimsonR | Red-shifted variant of ChR2. | 590 |
| |
| C1C2GA | Blue-shifted microbial opsin-based variant. | 455 |
| |
| Inhibitory (hyper-polarizing) | Halorhodopsin (eNph3.0) | Light-gated chloride channel found in halobacteria. Red-shifted, improved trafficking to membrane. | 589 |
|
| Archaerhodopsins (eArch3.0, eArchT 3.0) | Light gated proton pump from Halobrum. ArchT 3.0 has enhanced trafficking to membrane and light sensitivity. | 566 |
| |
| Jaws | Red shifted cruxhalorhodopsin from | 632 |
| |
| SwiChR(CA) | A mutated chimera of ChR that acts as a chloride-conducting anion channel; delayed off-kinetics rapidly corrected by brief red light pulse | 475 |
| |
| iChlocC | Mutant of ChR that permits chloride conduction with high selectivity and sensitivity | 476 |
| |
| GtACR1, 2, and ZipACR1 | Light-gated chloride channels from | ACR1: 515 | ||
| Aurora | Engineered anion-conducting channelrhodopsin; Red-shifted, with step-function capabilities | 517 |
| |
| Dual color actuators | BiPOLES | Dual color controller of neuronal activity that allows for excitation or inhibition based on photostimulation wavelength. | Inhibition: 490 |
|
FIGURE 6Somatic optogenetic stimulation versus terminal field optogenetic stimulation. (A) Optogenetic stimulation of a population of neurons at their soma will lead to downstream activation of all the projection targets of that population (as indicated by green activation arrows). (B) Terminal field stimulation using optogenetics. Here, an investigator may be interested in the function of Area 1 neuron projections to Area 2 specifically. By placing the laser directly above Area 2, the investigator will activate only those projection terminals to dissect the neural circuit function more precisely. Created with Biorender.com.
Common chemogenetic receptors and ligands with their associated properties and effects on neuronal activity.
| Receptor name | Mechanism of action | Effect on neuronal firing | Ligand | References |
| hM3Dq | Phospholipase C Dependent (activator) | Increased | CNO/clozpine/JHU37152/ | |
| hM1Dq | Phospholipase C Dependent (activator) | Increased | CNO |
|
| hM5Dq | Phospholipase C Dependent (activator) | Increased | CNO |
|
| hM4Di | Adenylate Cyclyase Dependent (inhibitor) | Decreased | CNO/clozpine/JHU37152/ | |
| hM2Di | Adenylate Cyclyase Dependent (inhibitor) | Decreased | CNO |
|
| Rq(R165L) | B-arrestin dependent | unknown | CNO |
|
| KORD | Adenylate Cyclyase Dependent (inhibitor) | Decreased | Salvinorin B |
|
| PSAM-5HT3 | Ligand gated cation channel | Increased | varinicline |
|
| PSAM-GlyR | Ligand gated anion channel | Decreased | varinicline |
|
FIGURE 7Optogenetic “sonar” method for targeting specific cellular populations for in vivo electrophysiology. Photostimulation “sonar” guides optrode to genetically targeted neurons expressing channelrhodopsin (ChR2) for extracellular electrophysiology recordings. Once the electrode is juxtaposed to a ChR2-expressing cell of interest, electrophysiological recordings may be performed. The optrode may have one or many channels for recording numerous cells simultaneously.